Speaker Profile
Biography
Dr. Manish Kohli graduated in 1990 from the University of Delhi with an Internal Medicine residency training at Cook County Hospital, Chicago from 1993-1996. After completing a 3-year Fellowship in Hematology-Oncology at the University of Arkansas from 1996-99, he joined the Central Arkansas Veteran HealthCare System in Little Rock as Staff physician with a joint appointment at the University of Arkansas for Medical Sciences (UAMS) as Assistant Professor of Medicine. During this time Dr. Kohli authoredco-authored several critical research trials including SWOG-9916, which introduced docetaxel chemotherapy in metastatic castrate resistant stage. In 2005, he joined University of Rochester, New York at the rank of Associate Professor in Medicine in which he oversaw critical areas of genomic and liquid biopsy based research. In June 2008, Dr. Kohli joined Mayo Clinic, Rochester, taking charge to build a comprehensive Genitourinary Oncology translational and clinical research program and was promoted to ConsultantProfessor in 2016 in the Department of Oncology. In 2018, he was appointed Vice-Chair of the Department of Genitourinary Oncology and as a Distinguished Moffitt Scholar at the Moffitt Cancer Center, Tampa, also appointed as the Director of the DeBartolo Family Personalized Medicine Institute. He joined Huntsman Cancer Institute-University of Utah in January 2020 as a Presidential Endowed Chair and Professor. Dr. Kohli also holds an Adjunct Faculty rank at the University of Illinois in Urbana Champagne where he works with colleagues on two different RO1s for ultrasensitive liquid biopsy profiling of molecular determinants of a variety of clinical outcomes. His research in advanced prostate cancer focusses on convergence sciences which combines population based trials with precision medicine concepts.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Victor Velculescu, Johns Hopkins
PMWC Award Ceremony
• Pioneer Honoree: Klaus Pantel, UKE & ELBS
• Luminary: Rebecca Fitzgerald, University of Cambridge
Keynote
• Klaus Pantel, UKE & ELBS
Advancing Minimal Residual Disease (MRD) Detection through cfDNA and cfRNA Profiling
• Chair: Luis Diaz, MSKCC
• Anne-Renee Hartman, Adela
Early Cancer Detection / Regulatory / Population Health
• Peter Bach, DELFI Diagnostics
• Joshua J. Ofman, GRAIL
Role of AI in Liquid Biopsies and Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics




